According to the implant recovery card (irc) received, (b)(6) male received onxane-21, sn (b)(4), on (b)(6) 2013 and required reintervention/explant on (b)(6) 2017 and subsequent replacement via onxa-19 due to undisclosed reason.Additional information is pending.
|
Multiple requests to the surgeon for additional clarifying information were made without success to acquire the following information: patient¿s current status, indication for re-operation, available operative notes, patient impact, and pertinent patient co-morbidities.No response was received.The manufacturing records for the onxane-21, sn (b)(4), were reviewed and it was confirmed that all records were controlled, available for review, and met all specifications.All lots passed functional testing and met release specifications.During the investigation no non-conformances or deviations were noted. onxane-21, sn (b)(4) implanted on (b)(6) 2013 in (b)(6) male; explanted on (b)(6) 2017 (3 years 295 days postop) and replaced by onxa-19, sn (b)(4) as reported to manufacturer's device tracking registration database.The explanted valve was not returned to the manufacturer and no other information was made available.The instructions for use (ifu) note the risk of explantation as a consequence of a complication, but we have no information on what complication may have prompted the procedure.Consequently, there is not enough information to know what, if any, relationship the explantation has to the valve.The ifu lists the following as potential adverse events: angina, cardiac arrhythmia, endocarditis, heart failure, hemolysis, hemolytic anemia, hemorrhage, myocardial infarction, prosthesis leaflet entrapment (impingement), prosthesis nonstructural dysfunction, prosthesis pannus, prosthesis perivalvular leak, prosthesis perivalvular leak, prosthesis regurgitation, prosthesis structural dysfunction, prosthesis thrombosis, stroke, and thromboembolism.It is possible that these complications could lead to reoperation and explantation.This event does not identify additional hazards or modify the probability and severity of existing hazards.
|
According to the implant recovery card (irc) received, (b)(6) male received onxane-21, sn (b)(4), on (b)(6) 2013 and required reintervention/explant on (b)(6) 2017 and subsequent replacement via onxa-19 due to undisclosed reason.
|